► The Josep Carreras Foundation and the Leo Messi Foundation sign a collaboration agreement to promote research into childhood leukaemia.

► "No child with leukaemia"is the name of the research project with which this collaboration is being launched. It will study a kind of rare childhood leukaemia that has a very poor prognosis.

"The better a process is understood, the better it can be controlled. Accessibility of blood has given us a rich understanding of leukemias".

"Leukaemia will be cured. Help us decide when". With this direct and forceful motto we present today the new awareness campaign of the Josep Carreras Leukaemia Foundation.

•  A Josep Carreras Leukaemia Research Institute (IJC) acute lymphoblastic leukaemia (ALL) research team, led by Dr. Josep Maria Ribera, has participated in a study published in the prestigious journal, The New England Journal of Medicine.

• The study shows that treatment with blinatumomab significantly prolongs the life expectancy of adult patients with certain kinds of leukaemia, in comparison with standard treatment with chemotherapy.

•  This discovery is an important step forward for improving the prognosis for adult ALL patients, a kind of leukaemia with an incidence of 30 new cases per million every year in Spain.

• The Josep Carreras Leukaemia Research Institute's (IJC) acute myeloid leukaemia research group, directed by Dr. Ruth M. Risueño, has published a paper in the prestigious journal Leukemia, considered to be the most important journal in the field of hematology.

• The study, the main author of which is Amaia Etxabe, has identified the importance of the serotonin receptor type 1 (HTR1) for therapy in acute myeloid leukaemia (AML).

• Acute myeloid leukaemia (AML) is the most common leukaemia in adults and accounts for 40% of all leukaemias in the western world. It is estimated that every year there are 15 new cases per million in our country. 

The Institute for Health Science Research Germans Trias i Pujol (IGTP), the Catalan Institute for Oncology (ICO) and the Josep Carreras Leukaemia Research Institute (IJC) have signed a collaboration agreement to promote scientific research into leukaemia and other malignant blood diseases.

• The agreement creates a strategic alliance between the three institutions to promote joint scientific research in the field of leukaemia and other malignant blood diseases.

• The alliance will make it possible to bring together the large number of cases and samples that are necessary to produce relevant, high-quality studies. It also integrates the staff at the three institutions in order to carry out global and interdisciplinary research projects. In all, the agreement brings together more than a hundred staff members.

• The agreement establishes the conditions under which research programmes at the Can Ruti campus in Badalona will be carried out, it complements the agreement already signed with Hospital Clínic and the University of Barcelona, and will be followed by another agreement with Hospital de Sant Pau.

"A great effort must therefore continue to be made to identify new biomarkers, as well as more specific therapeutic targets, in order to reduce the level of toxicity of treatments."